We collaborate with our partners in generic, specialty pharmaceutical, and biotechnology sectors who have extensive and diverse portfolios of ANDAs, 505(b)(2) NDAs, biosimilars, and new chemical entity (NCE) NDAs, either FDA-approved or under development. We continuously seek clients interested in licensing or co-marketing these products.
Please contact us for in-license or out-license consultations. We will respond to you shortly.